Matthijs van Luin

418 total citations
27 papers, 260 citations indexed

About

Matthijs van Luin is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Matthijs van Luin has authored 27 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 9 papers in Epidemiology and 5 papers in Virology. Recurrent topics in Matthijs van Luin's work include HIV/AIDS drug development and treatment (10 papers), Pneumocystis jirovecii pneumonia detection and treatment (6 papers) and HIV Research and Treatment (5 papers). Matthijs van Luin is often cited by papers focused on HIV/AIDS drug development and treatment (10 papers), Pneumocystis jirovecii pneumonia detection and treatment (6 papers) and HIV Research and Treatment (5 papers). Matthijs van Luin collaborates with scholars based in Netherlands, United Kingdom and United States. Matthijs van Luin's co-authors include David M. Burger, Paul F. M. Kuks, Clemens Richter, Ferdinand W.N.M. Wit, Marc van der Valk, C.P.W.G.M. Verwey-van Wissen, Bas Schouwenberg, Frank de Wolf, Angela Colbers and Jan M. Prins and has published in prestigious journals such as AIDS, Journal of Antimicrobial Chemotherapy and Clinical Pharmacokinetics.

In The Last Decade

Matthijs van Luin

27 papers receiving 257 citations

Peers

Countries citing papers authored by Matthijs van Luin

Since Specialization

Citations

This map shows the geographic impact of Matthijs van Luin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthijs van Luin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthijs van Luin more than expected).

Fields of papers citing papers by Matthijs van Luin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthijs van Luin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthijs van Luin. The network helps show where Matthijs van Luin may publish in the future.

Co-authorship network of co-authors of Matthijs van Luin

This figure shows the co-authorship network connecting the top 25 collaborators of Matthijs van Luin. A scholar is included among the top collaborators of Matthijs van Luin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthijs van Luin. Matthijs van Luin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis 2025 ·Pharmaceutics ·(unknown), Paul Hagedoorn, Bart L. Rottier, Floris Grasmeijer, Henderik W. Frijlink, Matthijs van Luin, (unknown), Peter Merkus, Daan J. Touw, Onno W. Akkerman, Gerard H. Koppelman	1
2	Dynamics of Low-Level Viremia and Immune Activation after Switching to a Darunavir-Based Regimen 2024 ·Viruses ·(unknown), (unknown), Wouter F.W. Bierman, Reinout van Crevel, Andy I. M. Hoepelman, Mark A. A. Claassen, Heidi Ammerlaan, Berend J. van Welzen, M.E.E. van Kasteren, S.F.L. van Lelyveld, Dorien de Jong, Kiki Tesselaar, Matthijs van Luin, Monique Nijhuis, Annemarie M. J. Wensing, (unknown)	2
3	Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay 2024 ·Pediatric Rheumatology ·(unknown), Sytze de Roock, (unknown), (unknown), (unknown), Alwin D. R. Huitema, Matthijs van Luin, Joost F. Swart	1
4	Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration 2024 ·Clinical Pharmacokinetics ·(unknown), (unknown), Esther V. Uijtendaal, (unknown), (unknown), Matthijs van Luin, Wouter Bult, Dylan W. de Lange, Nuray Kuşadasi, Joep M. Droogh, Toine C. G. Egberts, Erik A.M. Verschuuren, Maaike A. Sikma	1
5	Pharmacokinetics and Pharmacodynamics of Systemic Corticosteroids in Autoimmune and Inflammatory Diseases: A Review of Current Evidence 2024 ·Clinical Pharmacokinetics ·(unknown), (unknown), Caroline A. Lindemans, Marc H.A. Jansen, Stefan Nierkens, Alwin D. R. Huitema, Matthijs van Luin	3
6	Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study 2024 ·Journal of Cystic Fibrosis ·Renske van der Meer, Erik B. Wilms, (unknown), (unknown), Matthijs van Luin, (unknown), Harry Heijerman	4
7	De‐simplifying antiretroviral therapy from a single‐tablet to a two‐tablet regimen: Acceptance, patient‐reported outcomes, and cost savings in a multicentre study 2024 ·HIV Medicine ·(unknown), (unknown), Joost W. Vanhommerig, Nienke Langebeek, Elisabeth H. Gisolf, (unknown), Adriana J. J. Lammers, Annouschka M. Weijsenfeld, Marc van der Valk, (unknown), Reinout van Crevel, Matthijs van Luin, Kees Brinkman, David M. Burger	2
8	Vancomycin flushing reaction after intraperitoneal vancomycin: A case report 2023 ·Peritoneal Dialysis International ·(unknown), (unknown), Matthijs van Luin, Alferso C Abrahams	1
9	Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration 2023 ·British Journal of Clinical Pharmacology ·(unknown), Matthijs van Luin, Esther V. Uijtendaal, Noël Zahr, Maaike A. Sikma	3
10	Therapeutic Drug Monitoring of Ganciclovir in Cytomegalovirus-Infected Patients With Solid Organ Transplants and Its Correlation to Efficacy and Toxicity 2022 ·Therapeutic Drug Monitoring ·(unknown), J.E.E. Totté, (unknown), Arjan van Zuilen, Matthijs van Luin	7
11	Anti-Xa Levels in Morbidly Obese Patients Using Apixaban or Rivaroxaban, Before and After Bariatric Surgery 2021 ·Obesity Surgery ·(unknown), Hans de Boer, Bart Witteman, Marcel M.C. Hovens, Matthijs van Luin, Houshang Monajemi	9
12	Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies 2019 ·Alimentary Pharmacology & Therapeutics ·Melek Simsek, (unknown), Carmen S. Horjus, (unknown), Birgit I. Lissenberg‐Witte, (unknown), Matthijs van Luin, Margien L. Seinen, Chris J. Mulder, Dennis R. Wong, Nanne K.H. de Boer, Adriaan A. van Bodegraven	29
13	Monitoring of tobramycin serum concentrations in selected critically ill patients receiving selective decontamination of the digestive tract: a retrospective evaluation 2019 ·European Journal of Clinical Pharmacology ·(unknown), Matthijs van Luin, Ellen M. Mascini, (unknown), (unknown)	4
14	Drug-Drug Interactions Between Raltegravir and Pravastatin in Healthy Volunteers 2010 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Matthijs van Luin, Angela Colbers, (unknown), C.P.W.G.M. Verwey-van Wissen, Bas Schouwenberg, (unknown), (unknown), David M. Burger	12
15	Effect of posaconazole on the pharmacokinetics of fosamprenavir and vice versa in healthy volunteers 2010 ·Journal of Antimicrobial Chemotherapy ·Roger J. M. Brüggemann, Matthijs van Luin, (unknown), (unknown), (unknown), Bas Schouwenberg, David M. Burger	14
16	Adherence to HIV Therapeutic Drug Monitoring Guidelines in The Netherlands 2010 ·Therapeutic Drug Monitoring ·Matthijs van Luin, Ferdinand W.N.M. Wit, Colette Smit, (unknown), Eric J. F. Franssen, Clemens Richter, Frank P. Kroon, Frank de Wolf, David M. Burger	6
17	The Effect of Raltegravir on the Glucuronidation of Lamotrigine 2009 ·The Journal of Clinical Pharmacology ·Matthijs van Luin, Angela Colbers, C.P.W.G.M. Verwey-van Wissen, (unknown), M. van der Kolk, (unknown), (unknown), David M. Burger	20
18	Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations 2009 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Matthijs van Luin, Luuk Gras, Clemens Richter, Marc van der Valk, Jan M. Prins, Frank de Wolf, David M. Burger, Ferdinand W.N.M. Wit	26
19	Use of therapeutic drug monitoring in HIV disease 2008 ·Current Opinion in HIV and AIDS ·Matthijs van Luin, Paul F. M. Kuks, David M. Burger	21
20	[Acute caffeine intoxication after intake of 'herbal energy capsules']. 2008 ·PubMed ·(unknown), (unknown), Matthijs van Luin, (unknown)	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact